Engineered immune cells take aim at stubborn leukemia
NCT ID NCT07583303
First seen May 18, 2026 · Last updated May 25, 2026 · Updated 1 time
Summary
This early-phase study tests a new treatment called BSB-2002 for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying the NPM1 mutation. Before receiving the modified cells, patients get two chemotherapy drugs to prepare their body. The main goal is to find the safest dose and see if the therapy can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.